

Gianluca Perego

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4459090/publications.pdf>

Version: 2024-02-01

19
papers

242
citations

1651377

6
h-index

1113639

15
g-index

20
all docs

20
docs citations

20
times ranked

375
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5575-5578.	1.4	2
2	Osimertinib-related venous thromboembolism in non small lung cancer. <i>Thrombosis Research</i> , 2022, 210, 63-66.	0.8	3
3	Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 101-111.	1.0	2
4	Effects of hypertension on cancer survival: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13493.	1.7	13
5	Is there any place for novel agents in treating biliary tract cancer?. <i>Medical Oncology</i> , 2021, 38, 19.	1.2	1
6	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. <i>World Journal of Methodology</i> , 2021, 11, 95-109.	1.1	6
7	Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 211, 105883.	1.2	75
8	Not only a time-saving approach: Is it the time of subcutaneous formulation for daratumumab administration?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1751-1752.	0.5	2
9	Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 720748.	2.2	5
10	Surrogate endpoints for new anti-cancer drugs approvals: Are we follow the right way?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 448-449.	0.5	0
11	Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?. <i>Tumori</i> , 2021, , 030089162110616.	0.6	1
12	Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. <i>Medical Oncology</i> , 2020, 37, 81.	1.2	7
13	Association of steroid use with survival in solid tumours. <i>European Journal of Cancer</i> , 2020, 141, 105-114.	1.3	13
14	Past, present and future use of cytotoxic agents in oncology practice: A systematic review of Pubmed and ClinicalTrials.gov databases. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 2069-2072.	0.5	1
15	Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1458.	1.0	24
16	Continuous-infusion and outpatient setting: A chance for patients, a challenge for hospital pharmacists. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1715-1720.	0.5	2
17	Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug?. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 967-971.	0.5	3
18	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 783-794.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. <i>Cancers</i> , 2019, 11, 1174.	1.7	71